CD19 and hematologic disorder: In DLBCL, several bispecific antibodies are under clinical evaluation with promising results, including a CD19:CD3 antibody [197], a CD20:CD3 antibody [198] and a next-generation 2:1 CD20:CD3 antibody with two CD20 binders and higher potency for hematologic malignancies [199,200].